The impact of elective internal mammary and medial supraclavicular RT in breast cancer stage I–III
Elisabetta Bonzano, Radiation Oncologist at Fondazione IRCCS Policlinico in Università di Pavia, shared an article by Orit Kaidar on X;
“The EORTC 22922/10925 trial investigating regional nodal irradiation in stage I-III breast cancer: Outcomes according to locoregional and systemic therapies.
The EORTC 22922/10925 trial aimed to investigate the impact of elective internal mammary and medial supraclavicular (IM-MS) radiation therapy (RT) in breast cancer stage I–III, allowing for different locoregional and systematic therapies according to physician’s preference.
Different components of therapy influenced the site of the first breast cancer event.
More “intensive” local therapy: RT boost, mastectomy – reduced the risk for local and/or regional recurrence as first event – but these patients had more distant metastases as first event because of higher risk factors and less competing events.
IM-MS RT reduced regional recurrence as first event, with a borderline effect in reducing distant metastases as first event.
Breast cancer stage is a major driver of outcome regardless of the extent of therapy.”
Authors: Orit Kaidar, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023